Skip to main content
PLOS Neglected Tropical Diseases logoLink to PLOS Neglected Tropical Diseases
. 2024 Mar 22;18(3):e0012017. doi: 10.1371/journal.pntd.0012017

Assessing vulnerability for future Zika virus outbreaks using seroprevalence data and environmental suitability maps

Yannik Roell 1, Laura Pezzi 2,3, Anyela Lozano-Parra 4, Daniel Olson 1,5, Jane Messina 6,7, Talia Quandelacy 8, Jan Felix Drexler 9, Oliver Brady 10,11, Morteza Karimzadeh 12, Thomas Jaenisch 1,13,*
Editor: Josh M Colston14
PMCID: PMC10990225  PMID: 38517912

Abstract

The 2015–17 Zika virus (ZIKV) epidemic in the Americas subsided faster than expected and evolving population immunity was postulated to be the main reason. Herd immunization is suggested to occur around 60–70% seroprevalence, depending on demographic density and climate suitability. However, herd immunity was only documented for a few cities in South America, meaning a substantial portion of the population might still be vulnerable to a future Zika virus outbreak. The aim of our study was to determine the vulnerability of populations to ZIKV by comparing the environmental suitability of ZIKV transmission to the observed seroprevalence, based on published studies. Using a systematic search, we collected seroprevalence and geospatial data for 119 unique locations from 37 studies. Extracting the environmental suitability at each location and converting to a hypothetical expected seroprevalence, we were able to determine the discrepancy between observed and expected. This discrepancy is an indicator of vulnerability and divided into three categories: high risk, low risk, and very low risk. The vulnerability was used to evaluate the level of risk that each location still has for a ZIKV outbreak to occur. Of the 119 unique locations, 69 locations (58%) fell within the high risk category, 47 locations (39%) fell within the low risk category, and 3 locations (3%) fell within the very low risk category. The considerable heterogeneity between environmental suitability and seroprevalence potentially leaves a large population vulnerable to future infection. Vulnerability seems to be especially pronounced at the fringes of the environmental suitability for ZIKV (e.g. Sao Paulo, Brazil). The discrepancies between observed and expected seroprevalence raise the question: “why did the ZIKV epidemic stop with large populations unaffected?”. This lack of understanding also highlights that future ZIKV outbreaks currently cannot be predicted with confidence.

Author summary

After the ZIKV epidemic in the Americas, it remains unclear if and when a resurgence of the ZIKV could occur. We used publicly available data on environmental suitability of transmission as well as seroprevalence data to estimate future vulnerability to ZIKV outbreaks. Our results show a considerable discrepancy between the observed seroprevalence, from past exposure to the virus on one hand, and the environmental suitability, which raised the question why the epidemic subsided before reaching the expected herd immunization threshold in many locations. This lack of understanding also highlights that future ZIKV outbreaks currently cannot be predicted with confidence. Although we cannot provide an answer to the question why the epidemic subsided when it did, we present a better quantification and geospatial mapping of the potential vulnerability to future outbreaks, which will be crucial for decision makers to prepare for future outbreaks.

Introduction

Zika virus (ZIKV) is an arthropod-borne virus (arbovirus) belonging to the Flaviviridae family of the Flavivirus genus. The virus is transmitted to humans through the bite of infected mosquitoes from the Aedes (Ae.) genus, mainly Ae. aegypti and Ae. albopictus. Non-vectorial transmission routes have also been described, including sexual transmission, mother-to-child transmission (vertical transmission), and blood transfusion [1].

Two geographically distinct lineages of ZIKV have been identified so far: African and Asian. The African-ZIKV lineage likely originated in Eastern Africa and then spread west, causing sporadic or recurrent infections in African countries [2]. The first Asian ZIKV was isolated in Malaysia in the late 1960s and then the virus spread across Southeast Asia and the Pacific area, where the virus was responsible for localized outbreaks in Micronesia [3] and French Polynesia [4]. In 2015, the Asian lineage caused an explosive epidemic in the Americas; and the World Health Organization (WHO) declared ZIKV a Public Health Emergency of International Concern (PHEIC) in February 2016 [5]. Because of the similarities with other arboviral infections, Zika infections were first misdiagnosed as dengue at the beginning of the epidemic [5,6]. In 2017, ZIKV transmission in the Americas dropped sharply.

Several ZIKV seroprevalence studies have been performed in the Americas, Asia, and Africa; however, these estimates are affected by the strong cross-reactivity between anti-ZIKV antibodies and antibodies against other Flaviviruses, especially dengue virus (DENV) that is endemic in large areas of these continents where it co-circulates with ZIKV [7]. Neutralization tests are the serology gold standard because of their capacity to differentiate ZIKV infections from other closely-related viruses, while rapid immunochromatographic tests (RDT) and enzyme-linked immunosorbent assay (ELISA) have proved to be generally characterized by low specificity [813].

The end of the large outbreak in the Americas was attributed to evolving population immunity [14]. The expected herd immunity threshold for Zika virus was estimated at around 65% [3,13]. Seroprevalence estimates for the bigger cities along the Atlantic coast in Brazil confirmed this estimate [13,15], but smaller cities more inland in Brazil seem not to have been affected to the same degree [16]. Because the rapid end of the ZIKV epidemic in the Americas was poorly understood, we aimed to evaluate potential vulnerability for future epidemics. Here we analyze seroprevalence estimates and correlate these with environmental suitability for ZIKV transmission. Our hypothesis is that areas with high environmental suitability and comparably lower seroprevalence estimates may be at future risk for ZIKV emergence.

Methods

We plotted (a) published seroprevalence results from the literature (observed seroprevalence) and compared these with (b) environmental suitability maps. The difference between the environmental suitability and observed seroprevalence was used to determine (c) the vulnerability of a location having a severe outbreak if another epidemic occurred. The risk categories (high, low, or very low risk) were combined with perceived covariates to (d) determine if any differences between the risk categories exist.

Literature search for seroprevalence estimates

We retrieved geospatial seroprevalence data for Zika virus from PubMed and LILACS on October 22, 2021. Using “seroprevalence zika” as the search term, 139 records were returned. Each of the abstracts were reviewed by one person to exclude papers that did not meet our criteria. Afterwards, one reviewer screened the full text of the remaining papers, and a second reviewer was used to confirm papers that were excluded. We found 37 eligible studies that included point specific ZIKV seroprevalence (Fig 1). An eligible study included point location seroprevalence values for humans, the geographic region was either in the Americas, Africa, or Asia/Oceania, and participants were not symptomatic or febrile patients. For studies without geolocation information reported, we reached out to the authors via email up to three times before eliminating that record. Locations in Oceania are binned into the Asia group in the remaining paper due to proxy. After removing populations that were symptomatic or febrile patients, each location from a study was divided into one of four populations: pregnant women, blood donors, community, and other. From the 37 studies, 119 unique locations were identified across 26 different countries (Fig 2). If more than one seroprevalence estimate was available from a single location (e.g. sequential surveys), we kept the latest and highest value.

Fig 1. Flow chart of literature search and screening results.

Fig 1

Fig 2.

Fig 2

(A) Global study locations with sample size and serological assay group (NTs–neutralization tests and Other) and showing greater detail for (B) the Americas, (C) Africa, and (D) Asia. The world administrative boundary basemap is from https://public.opendatasoft.com/explore/dataset/world-administrative-boundaries/.

The serology assays used were grouped into two categories, according to their performances in terms of sensitivity and specificity: (1) neutralization tests (NT) and (2) all other tests which includes enzyme-linked immunosorbent assay (ELISA), rapid diagnostic test (RDT), microsphere immunoassay (MIA), and hemagglutination inhibition assay (HIA). These categories were chosen because NTs are considered serology gold standards and the other tests are strongly affected by cross-reactivity with antibodies against other Flaviviruses, lacking specificity, or they lack sensitivity.

Environmental suitability maps

For environmental suitability, or ZIKV transmission risk, we used maps published by Messina, Kraemer [17]. While technically producing predictions of probability of one or more cases, these suitability maps have been previously shown to correlate with incidence [18]. The methodology is described in detail in the publication, but as a summary, these maps were made from ensemble boosted regression with ZIKV occurrence data in humans and absence background locations. Six covariates thought to influence ZIKV transmission were used to determine the relationship between presence or absence and the environmental conditions. The covariates are temperature suitability for dengue transmission to humans via Ae. aegypti and Ae. albopictus, minimum relative humidity, annual cumulative precipitation, enhanced vegetation index, and urban versus rural habitat type. At the time of the published environmental suitability map, many of the parameters the authors used were not measured experimentally for ZIKV but for the closely related DENV, which is why their covariates are for dengue transmission. The generated 5-km resolution environmental suitability map ranges from 0 to 1 with 1 being the most suitable.

Vulnerability estimation and mapping

To assess populations vulnerable to a ZIKV outbreak, we estimated the discrepancy between the observed seroprevalence and predicted ZIKV environmental suitability:

Vulnerability = Seroprevalence (from studies)–Environmental Suitability (from map) (1)

Areas with higher environmental suitability would be expected to have higher seroprevalence. While we understand that environmental suitability and expected seroprevalence is not a one-to-one relationship due to the herd immunity being reached around 60–70% seroprevalence [3], this is being used as a proxy to understand the differences between what is observed and expected. We believe areas that are vulnerable will be places where the environmental suitability is higher than the seroprevalence (negative vulnerability). Vulnerability has been divided into three categories (high, low, and very low risk) depending on the distribution of the data.

Exploratory data analysis

We examined the relationship between vulnerability and temperature (mean temperature in coldest quarter) [19], human population density [20], and socioeconomic status [21] using Spearman’s and Pearson’s correlation coefficients, as well as by visual inspection (Table 1). Socioeconomic status was chosen because people with lower socioeconomic status often live in areas with uncontrolled urbanization and deteriorating housing, water, and waste management systems which create ideal conditions for transmission of mosquito-borne disease [22,23]. All maps were resampled to have a resolution of 5 km and the values from the maps were extracted at each study location using ArcGIS Pro 2.8 [24]. If a point was not within a raster cell, the nearest value was used, except for points within French Guiana. Due to the socioeconomic status layer not depicting a value for French Guiana, we used the lowest value available for mainland France as the default value for all points in French Guiana. Finally, the Mann Whitney U test was implemented to determine if there are differences that can be detected between the high risk and low risk categories for the three predictor variables.

Table 1. Description of maps utilized within the exploratory data analysis of clusters.

Variable Global Range Description Source
Environmental Suitability 0–1 Environmental suitability for Zika virus with higher values indicating more suitable Messina, Kraemer [17]
Temperature -66–29°C Mean temperature of coldest quarter Fick and Hijmans [19]
Human
Population
Density
0–103341 ppl / km2 Estimated total number of people per cell Doxsey-Whitfield, MacManus [20]
Socioeconomic
Status
0–1020 Purchasing power parity Nordhaus and Chen [21]

Results

Data selection

The data from the 119 locations cover very low (0%, seven locations with a sample size ranging from 11 to 366) to high seroprevalence (62%, sample size = 105), with studies ranging in sample size from 11 to 2120 individuals (Fig 2). The most common of the four distinct populations assigned to each location was community (N = 75), with pregnant women being the least (N = 6). Blood donors were designated in 20 locations and a total of 18 locations assigned as other. The average seroprevalence for ZIKV was 16%. Africa had the lowest average seroprevalence (8%, SD = 8%), Asia’s average seroprevalence was 15% (SD = 13%), and the Americas showed the highest average seroprevalence (24%, SD = 18%). No location in Africa had a higher seroprevalence than 50% while two locations in Asia and six locations in the Americas scored above 50%. Only 36 locations used a gold standard NT assay while 83 locations used an assay assigned in the other group.

All three continents were represented about equally with the number of locations (Africa N = 37, Americas N = 38, and Asia N = 44), with dates of sample collection ranging from July 2010 to June 2019 in Africa, December 2015 to December 2018 in the Americas, and December 2012 to October 2019 in Asia. Africa had the most countries represented with 12 countries, Asia had 9 countries represented, and the Americas had 5 countries represented. The most locations in one country were in French Guiana (N = 22) with the remaining countries in the Americas ranging between 2–6. Malaysia had 15 locations and Indonesia had 14 locations while the remaining countries in Asia ranged between 1–5 locations. Africa was evenly distributed with 1–8 locations per country. Detailed information for each study can be found in S1 Table.

Vulnerability

The three classes of vulnerability (high, low, and very low risk) were chosen based on the distribution of environmental suitability vs seroprevalence data (Fig 3). A value of 0.6 was used as the cutoff to distinguish between the areas with higher vs lower environmental suitability and a value of 0.5 was used as the cutoff to distinguish between the areas with higher vs lower seroprevalence. The cutoff values were chosen based on the division seen when visualizing the data. Locations that have an environmental suitability value greater than 0.6 and a seroprevalence less than 0.5 are indicated as high-risk population. A total of 69 locations (58%) fell within the high risk category. Locations with an environmental suitability value greater than 0.6 and a seroprevalence greater than 0.5 or an environmental suitability value less than 0.6 and a seroprevalence less than 0.5 were considered low risk, although these two different sub-categories have different underlying risk profiles. A total of 47 locations (39%) fell within this low risk category. Locations with an environmental suitability value less than 0.6 and a seroprevalence greater than 0.5 were evaluated as being very low risk. A total of 3 locations (3%) fell within the very low risk category. The difference between the low risk categories is that the very low risk has a low transmission risk with high seroprevalence, resulting in an outbreak unlikely to develop into a major outbreak due to existing herd immunity. The low risk either has a low transmission risk, resulting in the risk of a small outbreak if transmission is established, or has a high transmission risk but also has a high seroprevalence, resulting in a major outbreak not likely occurring due to herd immunity. The distribution of vulnerability categories along with environmental suitability can be found in Fig 4.

Fig 3. Division of vulnerability based on the difference between seroprevalence and environmental suitability.

Fig 3

NTs: neutralization tests.

Fig 4.

Fig 4

(A) Global distribution of vulnerability for ZIKV with environmental suitability depicted and showing greater detail for (B) the Americas, (C) Africa, and (D) Asia. The environmental suitability map is from Messina, Kraemer [17] and the world administrative boundary basemap is from https://public.opendatasoft.com/explore/dataset/world-administrative-boundaries/.

Exploratory data analysis

We investigated temperature, population density, and socioeconomic status as candidate explanatory variables for vulnerability. Using Spearman’s and Pearson’s correlation, all variables were statistically significant (p-value < 0.5) with at least one of the correlation metrics and negatively correlated with vulnerability. Temperature and vulnerability were significantly correlated using Pearson’s correlation (r = -0.25, p-value = 0.006), as well as population density (Pearson: r = -0.25, p-value = 0.006). Socioeconomic status was significantly correlated with vulnerability using both methods (Spearman: r = -0.34, p-value = 0.0001; Pearson: r = -0.21, p-value = 0.03).

The data was divided into two groups for the Mann Whitney U test: high risk points as one group and low risk points having a seroprevalence below 0.5 as another group. The two groups were significantly different regarding temperature (p-value = 0.004) and socioeconomic status (p-value = 0.01). For population density, the two groups did not show a statistically significant difference (p-value > 0.05) using the Mann Whitney U test.

Discussion

Here we present an assessment of potential vulnerability for future ZIKV transmission and subsequent outbreaks based on seroprevalence and environmental suitability. ZIKV resurgence remains a real threat for Latin America where many regions seem to have reached lower seroprevalence during the ZIKV epidemic than what would be considered protective on a population level, despite environmental suitability. The herd immunization threshold for ZIKV was estimated at around 65% based on data from Yap Island, Micronesia [3] and Salvador de Bahia, Brazil [13]. The reason why the ZIKV epidemic rapidly subsided in Latin America in 2016–17 remains poorly understood, in spite of the fact that models based on incidence trends (not seroprevalence) were able to predict that most major cities in Latin America had experienced a transmission peak before 2018 and would not experience high case numbers in 2018 and onwards [14]. In some areas, co-circulation of other arboviruses such as chikungunya virus (CHIKV; hardly affected South America between 2015 and 2017) and DENV (with the four serotypes hyper-endemic in many Latin American countries) might have played a role in replacing ZIKV transmission [25]. Since these arboviruses share the same hosts and vectors, several factors such as viral competition in both humans and mosquitoes, or existing population immunity against these pathogens, could have influenced ZIKV transmission patterns.

For Africa, the assessment of vulnerability is more uncertain, even if we observed regions with lower seroprevalence estimates despite high environmental suitability for ZIKV transmission. Population immunity to ZIKV in Africa is likely affected by ongoing transmission of other related flaviviruses. In the past, ZIKV outbreaks and clusters of microcephaly or Guillain Barré Syndrome were not reported–but the surveillance systems in Africa might also not be equipped to detect a signal unless very prominent.

Limitations of the study

The relationship between environmental suitability and transmission probability is likely non-linear. For our purposes, we have simplified this relationship to be linear. We also acknowledge that uncertainties regarding the mapping scale and location data can lead to misinterpretations, especially since the suitability map was produced early in the Zika epidemic. The underlying environmental suitability map lacks granularity, which has the potential to produce questionable results, at least in the small scale, which means the data needs to be interpreted with caution and we therefore recommend interpreting the results as an approximation of the true risk and the true location.

Our data is based on different populations (pregnant women, blood donors, community, and other special populations) whose representativity cannot be validated, as well as on heterogenous testing strategies and assays, which are shown in Fig 3. We acknowledge that different assay performance has an influence on the precision of the seroprevalence estimates, which we cannot adjust for in this analysis. This influence would likely not alter the overall interpretation of the remaining pockets of vulnerable populations.

We assumed that ZIKV circulation induces protective immunity against both homologous and heterologous ZIKV lineages, since cross-neutralization has been observed using both human and murine immune sera [26]. However, higher titers are always observed with the homologous strain and the introduction of heterologous ZIKV lineage in an area where it has never circulated before (e.g. African lineage imported into America) can possibly have an impact on population susceptibility. Also, a decline in ZIKV neutralizing antibodies over time after natural infection has been observed, underlying that previous ZIKV circulation is not synonymous of protection [27].

Conclusion

Our results show a potential vulnerability for increased future ZIKV transmission in many areas of Latin America, as well as in Africa and Asia where anti-ZIKV seroprevalence rates are low and environmental suitability for transmission is high. Because of the difference in the background epidemiology of ZIKV and related flaviviruses in Asia and Africa, this finding needs to be interpreted cautiously outside of Latin America.

The recent resurgence of other arboviruses in Latin America suggests that Zika re-emergence might also be a risk in areas where population immunity was not reached or has decreased. Acknowledging the inherent limitations, seroprevalence surveys can be a useful tool to assess the population vulnerability to future outbreaks.

Supporting information

S1 Table. The dataset generated from extracting data from seroprevalence studies and values from associated maps (minimal data set for analysis).

(XLSX)

pntd.0012017.s001.xlsx (31.2KB, xlsx)

Data Availability

All relevant data are in the manuscript and its supporting information files.

Funding Statement

The author(s) received no specific funding for this work.

References

  • 1.Sharma A, Lal SK. Zika Virus: Transmission, Detection, Control, and Prevention. Frontiers in Microbiology. 2017;8. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Faye O, Freire CCM, Iamarino A, Faye O, de Oliveira JVC, Diallo M, et al. Molecular Evolution of Zika Virus during Its Emergence in the 20th Century. PLOS Neglected Tropical Diseases. 2014;8(1):e2636. doi: 10.1371/journal.pntd.0002636 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Duffy MR, Chen T-H, Hancock WT, Powers AM, Kool JL, Lanciotti RS, et al. Zika virus outbreak on Yap Island, federated states of Micronesia. New England Journal of Medicine. 2009;360(24):2536–43. doi: 10.1056/NEJMoa0805715 [DOI] [PubMed] [Google Scholar]
  • 4.Musso D, Bossin H, Mallet HP, Besnard M, Broult J, Baudouin L, et al. Zika virus in French Polynesia 2013–14: anatomy of a completed outbreak. The Lancet Infectious Diseases. 2018;18(5):e172–e82. doi: 10.1016/S1473-3099(17)30446-2 [DOI] [PubMed] [Google Scholar]
  • 5.Musso D, Gubler DJ. Zika Virus. Clin Microbiol Rev. 2016;29(3):487–524. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Gubler DJ, Vasilakis N, Musso D. History and Emergence of Zika Virus. J Infect Dis. 2017;216(suppl_10):S860–S7. doi: 10.1093/infdis/jix451 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Guo C, Zhou Z, Wen Z, Liu Y, Zeng C, Xiao D, et al. Global epidemiology of dengue outbreaks in 1990–2015: a systematic review and meta-analysis. Frontiers in cellular and infection microbiology. 2017;7:317. doi: 10.3389/fcimb.2017.00317 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Chan KR, Ismail AA, Thergarajan G, Raju CS, Yam HC, Rishya M, et al. Serological cross-reactivity among common flaviviruses. Frontiers in Cellular and Infection Microbiology. 2022;12. doi: 10.3389/fcimb.2022.975398 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Low SL, Leo YS, Lai YL, Lam S, Tan HH, Wong JCC, et al. Evaluation of eight commercial Zika virus IgM and IgG serology assays for diagnostics and research. PLOS ONE. 2021;16(1):e0244601. doi: 10.1371/journal.pone.0244601 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Andreata-Santos R, Pereira SS, Pereira LR, Félix AC, Romano CM, de Souza Ferreira LC. Specificity of NS1-based immunochromatographic tests for dengue virus with regard to the Zika virus protein. International Journal of Infectious Diseases. 2020;95:276–8. doi: 10.1016/j.ijid.2020.04.012 [DOI] [PubMed] [Google Scholar]
  • 11.Khoo H, Lee H, Khor C, Tan K, AbuBakar S. Evaluation of commercial serological assays in Malaysia for detection of anti-Zika virus antibodies. Tropical biomedicine. 2021;38(4):613–21. doi: 10.47665/tb.38.4.105 [DOI] [PubMed] [Google Scholar]
  • 12.Nurtop E, Villarroel PMS, Pastorino B, Ninove L, Drexler JF, Roca Y, et al. Combination of ELISA screening and seroneutralisation tests to expedite Zika virus seroprevalence studies. Virol J. 2018;15(1):192. doi: 10.1186/s12985-018-1105-5 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Netto EM, Moreira-Soto A, Pedroso C, Hoser C, Funk S, Kucharski AJ, et al. High Zika Virus Seroprevalence in Salvador, Northeastern Brazil Limits the Potential for Further Outbreaks. mBio. 2017;8(6). doi: 10.1128/mBio.01390-17 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.O’Reilly KM, Lowe R, Edmunds WJ, Mayaud P, Kucharski A, Eggo RM, et al. Projecting the end of the Zika virus epidemic in Latin America: a modelling analysis. BMC Med. 2018;16(1):180. doi: 10.1186/s12916-018-1158-8 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Lowe R, Barcellos C, Brasil P, Cruz OG, Honorio NA, Kuper H, et al. The Zika Virus Epidemic in Brazil: From Discovery to Future Implications. Int J Environ Res Public Health. 2018;15(1). doi: 10.3390/ijerph15010096 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Brady OJ, Osgood-Zimmerman A, Kassebaum NJ, Ray SE, de Araújo VE, da Nóbrega AA, et al. The association between Zika virus infection and microcephaly in Brazil 2015–2017: An observational analysis of over 4 million births. PLoS medicine. 2019;16(3):e1002755. doi: 10.1371/journal.pmed.1002755 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Messina JP, Kraemer MU, Brady OJ, Pigott DM, Shearer FM, Weiss DJ, et al. Mapping global environmental suitability for Zika virus. Elife. 2016;5. doi: 10.7554/eLife.15272 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Bhatt S, Gething PW, Brady OJ, Messina JP, Farlow AW, Moyes CL, et al. The global distribution and burden of dengue. Nature. 2013;496(7446):504–7. doi: 10.1038/nature12060 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Fick SE, Hijmans RJ. WorldClim 2: new 1-km spatial resolution climate surfaces for global land areas. International Journal of Climatology. 2017;37(12):4302–15. [Google Scholar]
  • 20.Doxsey-Whitfield E, MacManus K, Adamo SB, Pistolesi L, Squires J, Borkovska O, et al. Taking Advantage of the Improved Availability of Census Data: A First Look at the Gridded Population of the World, Version 4. Papers in Applied Geography. 2015;1(3):226–34. [Google Scholar]
  • 21.Nordhaus WD, Chen X. Global Gridded Geographically Based Economic Data (G-Econ), Version 4. Palisades, New York: NASA Socioeconomic Data and Applications Center (SEDAC); 2016. [Google Scholar]
  • 22.Grace MP, Aisling MV, Luxi Q, Nuria Sanchez C, Julia MP, Enny SP, et al. Socioeconomic risk markers of arthropod-borne virus (arbovirus) infections: a systematic literature review and meta-analysis. BMJ Global Health. 2022;7(4):e007735. doi: 10.1136/bmjgh-2021-007735 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Gould E, Pettersson J, Higgs S, Charrel R, de Lamballerie X. Emerging arboviruses: Why today? One Health. 2017;4:1–13. doi: 10.1016/j.onehlt.2017.06.001 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.ESRI. ArcGIS PRO: Release 2.8. Redlands, CA: Environmental Systems Research Institute; 2021. [Google Scholar]
  • 25.Magalhaes T, Braga C, Cordeiro MT, Oliveira ALS, Castanha PMS, Maciel APR, et al. Zika virus displacement by a chikungunya outbreak in Recife, Brazil. PLoS Negl Trop Dis. 2017;11(11):e0006055. doi: 10.1371/journal.pntd.0006055 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26.Marchi S, Dragoni F, Boccuto A, Idoko OT, Zazzi M, Sow S, et al. Neutralizing activity of African lineage Zika virus immune sera towards Asian lineage. Acta Trop. 2023;237:106736. doi: 10.1016/j.actatropica.2022.106736 [DOI] [PubMed] [Google Scholar]
  • 27.Montoya M, Collins M, Dejnirattisai W, Katzelnick LC, Puerta-Guardo H, Jadi R, et al. Longitudinal Analysis of Antibody Cross-neutralization Following Zika Virus and Dengue Virus Infection in Asia and the Americas. J Infect Dis. 2018;218(4):536–45. doi: 10.1093/infdis/jiy164 [DOI] [PMC free article] [PubMed] [Google Scholar]
PLoS Negl Trop Dis. doi: 10.1371/journal.pntd.0012017.r001

Decision Letter 0

Andrea Marzi, Josh M Colston

21 Sep 2023

Dear Dr. Jaenisch,

Thank you very much for submitting your manuscript "Assessing vulnerability for future Zika virus outbreaks using seroprevalence data and environmental suitability maps" for consideration at PLOS Neglected Tropical Diseases. As with all papers reviewed by the journal, your manuscript was reviewed by members of the editorial board and by several independent reviewers. In light of the reviews (below this email), we would like to invite the resubmission of a significantly-revised version that takes into account the reviewers' comments.

Please revise the manuscript to incorporate the comments of the three reviewers. In particular, include a justification for restricting the scope of the analysis to Africa and the Americas to the exclusion of Asia, and for limiting the literature database search to PubMed.

We cannot make any decision about publication until we have seen the revised manuscript and your response to the reviewers' comments. Your revised manuscript is also likely to be sent to reviewers for further evaluation.

When you are ready to resubmit, please upload the following:

[1] A letter containing a detailed list of your responses to the review comments and a description of the changes you have made in the manuscript. Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out.

[2] Two versions of the revised manuscript: one with either highlights or tracked changes denoting where the text has been changed; the other a clean version (uploaded as the manuscript file).

Important additional instructions are given below your reviewer comments.

Please prepare and submit your revised manuscript within 60 days. If you anticipate any delay, please let us know the expected resubmission date by replying to this email. Please note that revised manuscripts received after the 60-day due date may require evaluation and peer review similar to newly submitted manuscripts.

Thank you again for your submission. We hope that our editorial process has been constructive so far, and we welcome your feedback at any time. Please don't hesitate to contact us if you have any questions or comments.

Sincerely,

Josh M Colston, Ph.D.

Guest Editor

PLOS Neglected Tropical Diseases

Andrea Marzi

Section Editor

PLOS Neglected Tropical Diseases

***********************

Please revise the manuscript to incorporate the comments of the three reviewers. In particular, include a justification for restricting the scope of the analysis to Africa and the Americas to the exclusion of Asia, and for limiting the literature database search to PubMed.

Reviewer's Responses to Questions

Key Review Criteria Required for Acceptance?

As you describe the new analyses required for acceptance, please consider the following:

Methods

-Are the objectives of the study clearly articulated with a clear testable hypothesis stated?

-Is the study design appropriate to address the stated objectives?

-Is the population clearly described and appropriate for the hypothesis being tested?

-Is the sample size sufficient to ensure adequate power to address the hypothesis being tested?

-Were correct statistical analysis used to support conclusions?

-Are there concerns about ethical or regulatory requirements being met?

Reviewer #1: See below

Reviewer #2: (No Response)

Reviewer #3: The text clearly articulates the objective of the study, which is to test the hypothesis that regions that areas with high environmental suitability and comparably lower seroprevalence estimates may be at future risk for ZIKV emergence.

To test the hypothesis that regions characterized by high environmental suitability and relatively lower seroprevalence estimates may face future risks related to ZIKV emergence, it is essential to consider a broader geographical scope. Excluding regions such as Southeast Asia from the analysis could limit the applicability of the findings and hinder a comprehensive understanding of the global Zika virus risk landscape. Given the uncertainty surrounding Zika virus evolution, providing a rationale for the exclusion of Southeast Asia becomes crucial. While Southeast Asian populations are thought to exhibit some resistance to ZIKV infection, the ongoing trends of globalization and international travel create a significant risk for the potential establishment of endemic ZIKV circulation in this region. This underscores the importance of justifying the decision to exclude Southeast Asia from the analysis.

In the context of conducting a literature search for seroprevalence estimates, it is acknowledged that PubMed stands as the suitable database for bioscience-related inquiries. However, it is important to address the question of why PubMed was not supplemented with other databases to enhance the comprehensiveness of information retrieval.

The furnished information delineates the methodology employed in the research to evaluate the correlation among observed seroprevalence, environmental suitability maps, vulnerability, and risk categories. Nevertheless, with regard to the adequacy of the sample size for ensuring adequate statistical power in addressing the tested hypothesis, augmenting the dataset from other sources would have augmented the information.

The statistical analyses employed to support the conclusions are considered acceptable.

No ethical concerns.

--------------------

Results

-Does the analysis presented match the analysis plan?

-Are the results clearly and completely presented?

-Are the figures (Tables, Images) of sufficient quality for clarity?

Reviewer #1: See below

Reviewer #2: (No Response)

Reviewer #3: - In lines: 131 and 132: “Most of the locations for Africa were in French Guiana (N = 22) with the other 15 countries having between 1-8 locations represented.” French Guiana actually is in South America.

- Line 141. Defining vulnerability solely based on seroprevalence lower than environmental suitability leads to oversimplification of the results. This approach fails to identify other potential forms of vulnerability. In Figure 4, the Peruvian coastline does not exhibit environmental suitability, but it does not reflect vulnerability either. This is an error, as the presence of the vector mosquito, socio-economic conditions, temperature, and other factors are relevant in this area. Similarly, the state of Pernambuco experienced a high incidence of cases and possesses all the risk-inducing conditions. However, according to statistical analyses, it is depicted as a very low-risk area. This discrepancy raises questions about the effectiveness of the current assessment.

- Assuming a linear relationship may lead to inaccurate risk assessments, as the actual relationship between environmental suitability and transmission is likely more complex, potentially resulting in misallocation of resources for disease control.

-Table 1- Temperature -66-29C, is Mean temperature of coldest quarter. Source Fick and Hijmans (2017) correct?

--------------------

Conclusions

-Are the conclusions supported by the data presented?

-Are the limitations of analysis clearly described?

-Do the authors discuss how these data can be helpful to advance our understanding of the topic under study?

-Is public health relevance addressed?

Reviewer #1: See below

Reviewer #2: (No Response)

Reviewer #3: The limitations of analysis are clearly described. However, it fails in incorporate in the discussion, within the limitations of the review, the role of asymptomatic individuals in assessing vulnerability for potential Zika outbreaks in the future.

The rationale behind the omission of data from Asia, despite the prevailing uncertainty concerning the trajectory of the Zika Virus (ZIKV), should be elaborated upon. Incorporating data from Asia into the analysis is highly advisable as it aims to demonstrate that regions characterized by substantial environmental suitability and relatively lower seroprevalence estimates may potentially face future risks pertaining to the emergence of the Zika virus.

--------------------

Editorial and Data Presentation Modifications?

Use this section for editorial suggestions as well as relatively minor modifications of existing data that would enhance clarity. If the only modifications needed are minor and/or editorial, you may wish to recommend “Minor Revision” or “Accept”.

Reviewer #1: See below

Reviewer #2: (No Response)

Reviewer #3: N/A

--------------------

Summary and General Comments

Use this section to provide overall comments, discuss strengths/weaknesses of the study, novelty, significance, general execution and scholarship. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. If requesting major revision, please articulate the new experiments that are needed.

Reviewer #1: The manuscript submitted by Roell et al aims at examining estimating vulnerability to future Zika virus outbreaks. The authors make use of seroprevalence data and environmental suitability maps previously published.

It is a fascinating aim, but the study has major pitfalls. The biggest one being the serology data used – with no control of the representativeness of the studies included. The statistical analysis also lack substance.

Main comments:

- Seroprevalence data: the authors used a systematic search to retrieve geospatial seroprevalence data. A major criteria that is lacking in the selection process is the representativeness of the studied population: while the authors make sure the seroprevalence studies were done on human populations, it is critical to also control for the population considered. For example, the study with the highest seroprevalence (94%, Collins et al 2020) was done on a cohort of pregnant women. This might not be representative of the whole population. Another example: the study of Oderinde et al 2020 (prevalence of 75%) analyzed samples “from patients exhibiting febrile illness” – therefore the study is not describing the seroprevalence in the general population, but rather among people with Zika-like symptoms. This study should be removed. I suggest authors should carefully review the studies they include. When there is a doubt about the representativeness of the population (e.g. pregnant women), authors should discuss the impact on their analysis.

- Type of assay: Authors point out that different assays are used to produce estimates of seroprevalence, but don’t really discuss the difference in estimates, NT assays consistently give seroprevalence <25%, could the authors discuss this? It makes 100% of the corresponding locations in the ‘Low Risk’ category.

- Date of seroprevalence studies: authors set out to assess the ‘vulnerability to future ZIKV outbreaks’ – however the timing of the seroprevalence studies is not taken into account, even when multiple studies are available for the same country. Can the authors be more precise on their definition of future?

- Categories: the cutoff at 45% is not as clear to me as the authors state, why not 50%?

- Clustering: Authors chose 3 different risk categories - which makes 4 different areas on figures 3 and 5. Why did the authors perform a k-mean clustering using only 3 centroids? By definition it cannot match their handmade categories.

Minor comments:

- Line 131: French Guiana is in America, not Africa

- Line 179: “None of the explanatory variables were highly correlated with vulnerability” – define “highly”. Temperature is still statistically significantly correlated.

- Lines 220-222: “available seroprevalence data may be under-reported due to the high frequency of non-symptomatic infections and that the data are based on clinically apparent infections (Duong et al., 2017).” – do you mean epidemiological data?

Reviewer #2: This is an interesting study analysing post-epidemic seroprevalence estimates in the Americas and Africa and investigating their relationship with environments suitable for ZIKV infection. Firstly, I would like to congratulate the authors for piecing together and evaluating an extensive data set. Overall, I very much enjoyed reading this manuscript. The manuscript is well written, proper statistical methods of analysis have been carried out and well explained. I do have a few comments that I hope will help improving the manuscript, or maybe just give the authors food for thoughts.

The main problems I have with the current manuscript relate to review methodology and statistical analysis. Firstly, the authors used PubMed to examine 135 records matching the term “seroprevalence zika”, but I think it would be more appropriate to define a broader range of literature databases and search terms to determine a more appropriate search strategy. An example would be to include PubMed/MEDLINE, Web of Science, and Scopus in the scope, define several proximate terms other than “seroprevalence zika”, improve the flowchart and thus perhaps give a different perspective. In doing so, it is also felt that it would be helpful to include a table of information on the complete literature used in each database and the complete search syntax as a thinning document. I also feel that clarification is needed as to whether the reviewers independently screened the titles and abstracts, or if there are discrepancies in the reviewers' assessments, whether detailed methodology, such as by discussion or other third-party reviewer input, is addressed. Indeed, all relevant records may be worth considering, with some guidelines defined as set out below. It was also unclear whether ethical approval had been obtained. This is but food for thoughts, as I believe the current analysis to have been done appropriately.

https://pubmed.ncbi.nlm.nih.gov/30178033/ 

https://pubmed.ncbi.nlm.nih.gov/26134548/

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4915647/

A seemingly puzzling fact is also observed. The authors conceptualize vulnerability as an area of lower seroprevalence than environmental suitability and define it as three categories, with the basis for setting cut-off values being a clear division based on visual inspection of the data. In fact, it is felt that a more robust approach to accurately assess these relationships would be to use continuous variables and (model) risk assessment along more geospatial gradients, rather than assigning categories One of the main weaknesses of the K-means method is that it is designed for grouping under a mechanical algorithm that is only interested in the characteristics of the variables, and the correlation coefficient only evaluates linear relationships that cannot account for time delays, particularly in the analysis of complex indicators such as seroprevalence, may not adequately account for valid causal relationships. For example, temperature and vulnerability are described as positively correlated (r = 0.33) but are found to be very weakly correlated, population density and socio-economic status are also uncorrelated, and the high and low risk clusters do not seem to differ that much for any of the predictors, i.e. it appears very difficult to infer high environmental fitness for infection It appears to be very difficult to infer a high environmental suitability for infection.

Finally, as a comment out of curiosity, since the authors are engaged in a review of the propagation of ZIKA and an assessment of the relationship between the driving factors, how, practically speaking, is there a tangible contribution that can be made in the future? What is the significance and inherent importance of the original findings that can be drawn from this research, rather than simply a systematic scoping review or repeated exercise to fill knowledge gaps in new areas? I would not be too surprised if historical shifts in climate change, including recent extreme events, socio-economic factors and human mobility have played a major role in shaping the spatio-temporal abundances associated with ZIKA recurrence due to Vector migration and the complex direct or interaction patterns that exist between them It is not. Again, this is just food for thought.

Minor comments:

Line 71: I am not sure this statement is true; Although I feel that the low anti-ZIKV seroprevalence in many parts of Latin America and the Caribbean could be described to some extent, it may not necessarily mean that environmental suitability for infection is high. The authors have not been able to fully assess causality.

Lines 103-104: For reference, indicators other than Spearman's correlation coefficient (e.g., Pearson and Kendall) should also be evaluated to see the differences.

Reviewer #3: It is recommended that the rationale behind the exclusion of data from Asia, given the ongoing uncertainty surrounding the trajectory of the Zika Virus (ZIKV), should be thoroughly explained. The inclusion of Asian data in the analysis is strongly encouraged, as it has the potential to illustrate that regions characterized by significant environmental suitability and relatively lower seroprevalence estimates may indeed face future risks associated with the emergence of the Zika virus.

--------------------

PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

Reviewer #2: Yes: Keita Wagatsuma

Reviewer #3: No

Figure Files:

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at figures@plos.org.

Data Requirements:

Please note that, as a condition of publication, PLOS' data policy requires that you make available all data used to draw the conclusions outlined in your manuscript. Data must be deposited in an appropriate repository, included within the body of the manuscript, or uploaded as supporting information. This includes all numerical values that were used to generate graphs, histograms etc.. For an example see here: http://www.plosbiology.org/article/info%3Adoi%2F10.1371%2Fjournal.pbio.1001908#s5.

Reproducibility:

To enhance the reproducibility of your results, we recommend that you deposit your laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. Additionally, PLOS ONE offers an option to publish peer-reviewed clinical study protocols. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols

PLoS Negl Trop Dis. doi: 10.1371/journal.pntd.0012017.r003

Decision Letter 1

Andrea Marzi, Josh M Colston

20 Feb 2024

Dear Dr. Jaenisch,

We are pleased to inform you that your manuscript 'Assessing vulnerability for future Zika virus outbreaks using seroprevalence data and environmental suitability maps' has been provisionally accepted for publication in PLOS Neglected Tropical Diseases.

Before your manuscript can be formally accepted you will need to complete some formatting changes, which you will receive in a follow up email. A member of our team will be in touch with a set of requests.

Please note that your manuscript will not be scheduled for publication until you have made the required changes, so a swift response is appreciated.

IMPORTANT: The editorial review process is now complete. PLOS will only permit corrections to spelling, formatting or significant scientific errors from this point onwards. Requests for major changes, or any which affect the scientific understanding of your work, will cause delays to the publication date of your manuscript.

Should you, your institution's press office or the journal office choose to press release your paper, you will automatically be opted out of early publication. We ask that you notify us now if you or your institution is planning to press release the article. All press must be co-ordinated with PLOS.

Thank you again for supporting Open Access publishing; we are looking forward to publishing your work in PLOS Neglected Tropical Diseases.

Best regards,

Josh M Colston, Ph.D.

Academic Editor

PLOS Neglected Tropical Diseases

Andrea Marzi

Section Editor

PLOS Neglected Tropical Diseases

***********************************************************

Thank you for addressing all the comments thoroughly and congratulations on an excellent analysis and paper.

PLoS Negl Trop Dis. doi: 10.1371/journal.pntd.0012017.r004

Acceptance letter

Andrea Marzi, Josh M Colston

19 Mar 2024

Dear Dr. Jaenisch,

We are delighted to inform you that your manuscript, "Assessing vulnerability for future Zika virus outbreaks using seroprevalence data and environmental suitability maps," has been formally accepted for publication in PLOS Neglected Tropical Diseases.

We have now passed your article onto the PLOS Production Department who will complete the rest of the publication process. All authors will receive a confirmation email upon publication.

The corresponding author will soon be receiving a typeset proof for review, to ensure errors have not been introduced during production. Please review the PDF proof of your manuscript carefully, as this is the last chance to correct any scientific or type-setting errors. Please note that major changes, or those which affect the scientific understanding of the work, will likely cause delays to the publication date of your manuscript. Note: Proofs for Front Matter articles (Editorial, Viewpoint, Symposium, Review, etc...) are generated on a different schedule and may not be made available as quickly.

Soon after your final files are uploaded, the early version of your manuscript will be published online unless you opted out of this process. The date of the early version will be your article's publication date. The final article will be published to the same URL, and all versions of the paper will be accessible to readers.

Thank you again for supporting open-access publishing; we are looking forward to publishing your work in PLOS Neglected Tropical Diseases.

Best regards,

Shaden Kamhawi

co-Editor-in-Chief

PLOS Neglected Tropical Diseases

Paul Brindley

co-Editor-in-Chief

PLOS Neglected Tropical Diseases

Associated Data

    This section collects any data citations, data availability statements, or supplementary materials included in this article.

    Supplementary Materials

    S1 Table. The dataset generated from extracting data from seroprevalence studies and values from associated maps (minimal data set for analysis).

    (XLSX)

    pntd.0012017.s001.xlsx (31.2KB, xlsx)
    Attachment

    Submitted filename: YRoell_ZikaMS_comments_responses.docx

    pntd.0012017.s002.docx (22.7KB, docx)

    Data Availability Statement

    All relevant data are in the manuscript and its supporting information files.


    Articles from PLOS Neglected Tropical Diseases are provided here courtesy of PLOS

    RESOURCES